EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Serum Lactate Dehydrogenase as a Potential Biomarker for Lateral Lymph Node Metastasis in Thyroid Cancer Patients After Total Thyroidectomy

Fu Liang Sun, Zhi Qiang Sun, Jian Feng Cheng, Zhi Ming Song, Qing Qing Huang

Journal of Current Surgery · 2026

DOI: 10.14740/jcs1035 ↗

At a glance

Journal article in Journal of Current Surgery, 2026. Written by Fu Liang Sun and 4 co-authors. The full text is freely available (open access, CC BY-NC 4.0).

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

This study aimed to investigate the clinical significance of serum lactate dehydrogenase (LDH) as a potential biomarker in patients with thyroid cancer, particularly in association with lateral lymph node metastasis (MLN) after total thyroidectomy.

Methods

A total of 2,560 patients with thyroid tumors were divided into benign group (n = 612) and malignant group (n = 1,948). Serum LDH and thyroid-stimulating hormone (TSH) levels were measured within 3 days before surgery. Within the malignant group, three subgroups were further analyzed: cancer subgroup, n = 1,820; MLN subgroup, n = 50; and cancer + MLN subgroup, n = 78. Statistical analyses included t-tests, Chi-square tests, and one-way analysis of variance (ANOVA) with Tukey’s post-hoc tests, multivariable logistic regression, and receiver operating characteristic (ROC) curve analysis.

Results

Compared with the benign group, patients in the malignant group were younger (t = 13.79, P < 0.001), had higher body mass index (BMI, t = 1.97, P = 0.049), a greater proportion of males (χ2 = 4.35, P = 0.037), and lower levels of both TSH (t = 6.72, P < 0.001) and LDH (t = 3.12, P = 0.002). Subgroup analysis within the malignant group revealed that the MLN subgroup had significantly higher LDH levels (197.9 ± 47.14 IU/L) compared with both the cancer subgroup (178.9 ± 45.58 IU/L, t = 2.90, P = 0.004) and the cancer + MLN subgroup (174.3 ± 46.49 IU/L, t = 2.79, P = 0.006). No significant difference was observed between the cancer and cancer + MLN subgroups (P = 0.58). Multivariable logistic regression confirmed that LDH remained independently associated with MLN status after adjusting for age, sex, and BMI (odds ratio (OR) = 1.011, 95% confidence interval (CI): 1.004–1.018, P = 0.002). ROC analysis yielded an area under the curve (AUC) of 0.628 (95% CI: 0.553–0.702), with an optimal cut-off of 187.5 IU/L (sensitivity 56.0%, specificity 63.6%).

Conclusions

While serum LDH levels are lower in patients with newly diagnosed thyroid cancer compared with those with benign tumors, a significant elevation in LDH is observed in patients who develop lateral cervical MLN after total thyroidectomy. These findings demonstrate an association between elevated serum LDH and lateral neck recurrence, suggesting that LDH may serve as a useful adjunctive biomarker for monitoring lateral MLN during postoperative follow-up in thyroid cancer patients. Further prospective studies with serial LDH measurements are warranted to validate these findings.

Cite

APA

Sun, F. L., Sun, Z. Q., Cheng, J. F., Song, Z. M., & Huang, Q. Q. (2026). Serum Lactate Dehydrogenase as a Potential Biomarker for Lateral Lymph Node Metastasis in Thyroid Cancer Patients After Total Thyroidectomy. Journal of Current Surgery. https://doi.org/10.14740/jcs1035

Vancouver

Sun FL, Sun ZQ, Cheng JF, Song ZM, Huang QQ. Serum Lactate Dehydrogenase as a Potential Biomarker for Lateral Lymph Node Metastasis in Thyroid Cancer Patients After Total Thyroidectomy. Journal of Current Surgery. 2026. doi:10.14740/jcs1035

BibTeX
@article{Sun2026,
  author = {Sun, Fu Liang and Sun, Zhi Qiang and Cheng, Jian Feng and Song, Zhi Ming and Huang, Qing Qing},
  title = {Serum Lactate Dehydrogenase as a Potential Biomarker for Lateral Lymph Node Metastasis in Thyroid Cancer Patients After Total Thyroidectomy},
  journal = {Journal of Current Surgery},
  year = {2026},
  doi = {10.14740/jcs1035}
}
Start for free →